Overexpression of serum HMGB1 and IDO in esophageal squamous cell carcinoma patients: potential clinical auxiliary diagnostic markers and immunotherapeutic targets
Serum HMGB1 and IDO have a synergistic effect, they inhibit immune function and promote tumor progression in ESCC patients, and also lead to poor prognosis.
Authors
- Ming Ma
- Xingxiao Yang
- Yunqiang Mi
- Xiao-Ya Shang (ORCID: https://orcid.org/0000-0003-2193-1712)
- Yan Xi (ORCID: https://orcid.org/0000-0002-3451-8292)
- Wenxuan Cui (ORCID: https://orcid.org/0009-0006-7594-3822)
- Yinghao Niu
- Xueyuan Zhang
- Beixuan Huang
- Wei Zhao (ORCID: https://orcid.org/0000-0002-8520-2087)
- Xin Zhang (ORCID: https://orcid.org/0000-0002-1460-3676)
Institutions
- Hebei Medical University (CN)
- Central Military Commission (CN)
- Fourth Hospital of Hebei Medical University (CN)
- First Affiliated Hospital of Hebei Medical University (CN)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2024-09-09
- DOI
- https://doi.org/10.3389/fonc.2024.1452282
- Primary Topic
- Advanced Glycation End Products research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China
- Horizon 2020 Framework Programme